Welcome to our dedicated page for Mei Pharma news (Ticker: MEIP), a resource for investors and traders seeking the latest updates and insights on Mei Pharma stock.
MEI Pharma Inc (MEIP) is a clinical-stage biopharmaceutical company focused on developing novel oncology therapies, with an emphasis on oral treatments targeting specific cancer mechanisms. This page provides investors and industry observers with timely updates on the company’s clinical trials, regulatory milestones, financial performance, and strategic partnerships.
As a centralized resource for MEI Pharma news, this page aggregates press releases, earnings reports, and scientific updates related to its pipeline candidates including zandelisib (PI3K delta inhibitor) and ME-344 (mitochondrial inhibitor). Users can track progress across clinical development stages, from Phase 1 safety data to late-stage trial results.
The curated news collection serves investors seeking to monitor MEIP’s operational progress, partnership announcements with pharmaceutical companies, and presentations at major medical conferences. Content is organized chronologically and categorized for efficient navigation, ensuring stakeholders stay informed about developments impacting the company’s valuation and scientific trajectory.
Bookmark this page for direct access to MEI Pharma’s official communications, including FDA correspondence updates and analyses of trial data. Regular visitors gain a comprehensive view of the company’s position within the competitive oncology therapeutics sector without promotional bias.
MEI Pharma (MEIP) has reported its financial position for Q2 FY2025, with $23.7 million in cash and cash equivalents and no outstanding debt as of December 31, 2024. The company continues its previously announced strategic alternatives review, initiated in July 2024, exploring options including out-licensing opportunities and merger and acquisition possibilities to maximize stockholder value. Oppenheimer & Co. is serving as the exclusive financial advisor in this process.
The company has implemented cash preservation measures, including a staged reduction-in-force during the first half of fiscal year 2025. MEI Pharma notes that there is no guarantee the strategic review will result in any successful transactions, and updates will only be disclosed when legally required or upon completion of the evaluation process.
MEI Pharma (Nasdaq: MEIP) reported its financial results for the quarter ending September 30, 2024. The company is actively exploring strategic alternatives to maximize shareholder value, including out-licensing and M&A opportunities, with Oppenheimer & Co. as its exclusive financial advisor. MEI Pharma began cash preservation efforts in the first quarter of fiscal year 2025, including a reduction-in-force. The company holds $26.9 million in cash, cash equivalents, and short-term investments with no outstanding debt. There is no assurance that the exploration of strategic alternatives will result in any agreements or transactions, and the company does not expect to disclose further developments unless legally required or until the evaluation is complete.
MEI Pharma (Nasdaq: MEIP) reported its fiscal year end 2024 results, confirming the continuation of its strategic alternatives evaluation. The company announced on July 22, 2024, that it had begun this process to maximize stockholder value. Oppenheimer & Co., Inc. was engaged as the exclusive financial adviser for this review. Options under consideration include out-licensing existing programs and potential mergers or acquisitions.
To preserve cash, MEI initiated a reduction-in-force on August 1, 2024, which will progress in stages. While clinical development of voruciclib has been discontinued, some non-clinical activities for other drug candidates continue. As of June 30, 2024, MEI had $38.3 million in cash, cash equivalents, and short-term investments with no outstanding debt.
MEI Pharma (Nasdaq: MEIP) has announced the engagement of Oppenheimer & Co. Inc. as its exclusive financial advisor to assist in evaluating strategic alternatives. This move is part of the company's previously announced process to review potential options, with a focus on maximizing stockholder value. MEI Pharma emphasizes that there is no guarantee that this exploration will result in any agreements or successful transactions. The company plans to maintain discretion regarding the process and will only disclose developments if required legally or deemed appropriate by the Board of Directors.
MEI Pharma (Nasdaq: MEIP) has announced a strategic review, including potential transactions or an orderly wind-down, to maximize shareholder value. The company will implement a reduction-in-force and discontinue clinical development of voruciclib to preserve cash. Key leadership changes include:
1. CEO David M. Urso and CMO Richard Ghalie stepping down on August 1, 2024
2. Board Chairperson Charles V. Baltic III resigning immediately
3. CFO Justin File appointed as Acting CEO
4. Frederick W. Driscoll appointed as new Board Chairperson
The company will explore options such as out-licensing programs and M&A opportunities. If no advantageous alternatives are found, an orderly wind-down of operations will be considered.
MEI Pharma, a clinical-stage pharmaceutical company, reported positive results for the third quarter fiscal year 2024, highlighting promising clinical data for voruciclib and ME-344. The ongoing Phase 1 study evaluating voruciclib plus venetoclax in R/R AML patients showed anti-leukemic activity, with complete responses and significant decreases in Mcl-1 levels. MEI's Board of Directors is focused on advancing the voruciclib program, with a cash balance of $56.6 million. MEI also initiated research on a new ME-344 formulation and decided to prioritize clinical development of voruciclib. Financially, MEI had no debt, $56.6 million in cash, and believes its cash balance is sufficient for the next 12 months.
FAQ
What is the current stock price of Mei Pharma (MEIP)?
What is the market cap of Mei Pharma (MEIP)?
